Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness

Aim. To study atorvastatin (10 and 20 mg/d) effects on lipid, C-reactive protein, and fibrinogen levels, vascular wall structure and function in patients with coronary heart disease (CHD) and primary hyperlipidemia (PHL). Material and methods. In total, 50 CHD and PHL patients were randomized into t...

Full description

Bibliographic Details
Main Authors:	A. V. Susekov, T. A. Rozhkova, M. I. Tripoten’, O. A. Pogorelova, B. D. Kulev, T. V. Balakhonova, M. Yu. Zubareva, V. P. Masenko, A. N. Rogoza, V. V. Kukharchuk
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2007-06-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	atherosclerosis coronary heart disease dyslipidemia atorvastatin vascular wall endothelial function
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1255

Similar Items

Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen levels
by: A. V. Susekov, et al.
Published: (2006-12-01)

DYNAMICS OF MORPHOLOGICAL CHANGES IN BRACHIOCEPHALIC TRUNK ARTERIES INFLUENCED OF ATORVASTATIN THERAPY IN PATIENTS OF HIGH RISK
by: OA A Rubanenko
Published: (2018-09-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

Comparison between Protective Effects of Resveratrol and Atorvastatin against Atherogenic Dyslipidemia in Rats
by: Mehdi Kian, et al.
Published: (2023-12-01)

Effect of Atorvastatin And Garlic on Lipid Profile in Hyperlipidemic Patients
by: Zuhair M Hussien, et al.
Published: (2019-11-01)

Effect of Atorvastatin And Garlic on Lipid Profile in Hyperlipidemic Patients
by: Zuhair M Hussien, et al.
Published: (2019-11-01)

LIPRIMAR®. FIFTEEN YEARS OF EVIDENCE
by: A. V. Susekov, et al.
Published: (2016-01-01)

Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
by: Jaecheol Moon, et al.
Published: (2020-01-01)

An open-label prospective observational study to evaluate the efficacy and safety of alternate day versus daily dosing of atorvastatin in patients of dyslipidemia
by: Gulam Mohammad, et al.
Published: (2024-01-01)

EFFECTS OF ATORVASTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DYSLIPIDEMIA
by: N. M. Nikitina, et al.
Published: (2014-07-01)

Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis
by: Nur Aini Hasan, et al.
Published: (2024-03-01)

Atorvastatin: evidence base 15 years later
by: A. V. Susekov, et al.
Published: (2011-06-01)

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension
by: N. B. Amirov, et al.
Published: (1970-01-01)

Effectiveness of Lipid-lowering Therapy for the Secondary Prevention and Achievement of Therapeutic Goals in Atherosclerotic Cardiovascular Diseases in Accordance with the American College of Cardiology/American Heart Association 2018 Guidelines on the Management of Blood Cholesterol
by: Christy Sojan, et al.
Published: (2024-04-01)

Identification and treatment of patients with high cardiovascular risk
by: I. V. Sergienko, et al.
Published: (1970-01-01)

Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
by: G. A. Batrak, et al.
Published: (2010-06-01)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
by: Hae Won Jung, et al.
Published: (2023-09-01)

Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial
by: Jie-Eun Lee, et al.
Published: (2024-07-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

Impact of LDLR polymorphisms on lipid levels and atorvastatin’s efficacy in a northern Chinese adult Han cohort with dyslipidemia
by: Hong-Liang Zhao, et al.
Published: (2024-04-01)

Comparison between 20 mg versus 40 mg dose of atorvastatin among dyslipidemic patients associated with diabetes or coronary artery disease: a randomized clinical trial
by: Hassan Aboobaid, et al.
Published: (2017-06-01)

Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
by: Jae Hoon Kim, et al.
Published: (2022-08-01)

Vasoprotective statin effectiveness in patients with carotid atherosclerosis
by: Yu. B. Belousov, et al.
Published: (2007-10-01)

Anti-inflammatory effects of low- and high-dose atorvastatin therapy in patients with coronary heart disease and rheumatoid arthritis
by: V. S. Tutunov, et al.
Published: (2008-10-01)

Modern algorithms for statin therapy
by: V. A. Susekov
Published: (2023-11-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
by: M. V. Kim, et al.
Published: (2015-03-01)

Clinical role of apolipoproteins A and B
by: G. A. Chumakova, et al.
Published: (2011-12-01)

ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01)

Statin-induced myopathy associated with atorvastatin therapy in the elderly patient. Clinical case
by: Natalia A. Cherkasova, et al.
Published: (2021-10-01)

Dose-dependent effects of atorvastatin in the hospitalisation period of myocardial infarction
by: O. L. Barbarash, et al.
Published: (2013-06-01)

Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese Han Adults with Dyslipidemia
by: Chen C, et al.
Published: (2024-12-01)

Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
by: R. S. Karpov, et al.
Published: (2009-08-01)

A case of rhabdomyolysis after atorvastatin therapy of a liver transplant recipient receiving immunosuppressive therapy with cyclosporine
by: A. V. Shabunin, et al.
Published: (2021-06-01)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016-01-01)

Prediction and validation of common targets in atherosclerosis and non-small cell lung cancer influenced by atorvastatin
by: Yu-qian Li, et al.
Published: (2023-11-01)

EFFECTS OF AN EIGHT-WEEK ATORVASTATIN TREATMENT ON SPONTANEOUS CYTOKINE PRODUCTION BY THE BLOOD MONONUCLEAR LEUKOCYTES IN METABOLIC SYNDROME
by: I. D. Bespalovа, et al.
Published: (2014-11-01)

The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia
by: Bakhtawar Farooq, et al.
Published: (2024-05-01)